EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Minocycline inhibits rosacea-like inflammation through the TLR4-mediated NF-κB signaling pathway in vivo and in vitro

Piyan Hua, Ying Tu, Zhenghui Yang, Yunting He, Li He, Qiuyan Yao, Hua Gu iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0323598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Piyan Hua und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Minocycline, Rosacea, NF-kappa B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Yunnan Revitalization Talent Support Program..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rosacea is a chronic inflammatory skin disease characterized by multiple intricate pathogenic factors. Previous studies have substantiated the anti-inflammatory properties of minocycline and its potential therapeutic efficacy in treating rosacea. However, further elucidation of the underlying mechanism is warranted.

Methods

HaCaT cells and BALB/c mice were treated with LL37. Moreover, the effect of minocycline on rosacea was explored through the addition of an NF-κB inhibitor (PDTC) or overexpression of Toll-like receptor 4 (TLR4). The expression of related markers was detected by western blotting, immunofluorescence, ELISA, flow cytometry, etc.

Results

Minocycline suppressed dermal infiltration of inflammatory cells in rosacea-like mice and reduced the expression of inflammatory cytokines in rosacea-like mice and cells. Moreover, minocycline downregulated the expression of TLR4 and p-NF-κB thereby inhibiting ROS production. However, overexpression of TLR4 or the addition of PDTC counteracted the effects of minocycline by promoting cellular inflammation and ROS production. Mechanistically, minocycline hinders TLR4/TNF-α activation induced by LL37 in skin and cells to suppress the expression of inflammatory cytokines.

Conclusion

Minocycline alleviates inflammation progression in rosacea by downregulating TLR4 and inhibiting the activation of the NF-κB pathway, providing a scientific basis for subsequent clinical treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4MinocyclineRosaceaNF-kappa BSignal TransductionInflammationAnti-Inflammatory AgentsAnimalsHumansMiceMice, Inbred BALB CReactive Oxygen SpeciesCathelicidinsCytokinesHaCaT Cells

Substanzen

Toll-Like Receptor 4MinocyclineNF-kappa BReactive Oxygen SpeciesCathelicidinsTLR4 protein, humanCytokinesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China.

ORCID-Profile: Hua Gu

Förderung

  • the Yunnan Revitalization Talent Support Program.

Zitieren

APA

Hua, P., Tu, Y., Yang, Z., He, Y., He, L., Yao, Q., & Gu, H. (2025). Minocycline inhibits rosacea-like inflammation through the TLR4-mediated NF-κB signaling pathway in vivo and in vitro. PLOS One. https://doi.org/10.1371/journal.pone.0323598

Vancouver

Hua P, Tu Y, Yang Z, He Y, He L, Yao Q, et al. Minocycline inhibits rosacea-like inflammation through the TLR4-mediated NF-κB signaling pathway in vivo and in vitro. PLOS One. 2025. doi:10.1371/journal.pone.0323598

BibTeX
@article{Hua2025,
  author = {Hua, Piyan and Tu, Ying and Yang, Zhenghui and He, Yunting and He, Li and Yao, Qiuyan and Gu, Hua},
  title = {Minocycline inhibits rosacea-like inflammation through the TLR4-mediated NF-κB signaling pathway in vivo and in vitro},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0323598}
}
Kostenlos starten →